The use of fecal calprotectin testing in ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
The use of fecal calprotectin testing in paediatric disorders: a position paper of the european society for paediatric gastroenterology and nutrition gastroenterology committee
Auteur(s) :
Ribes-Koninckx, Carmen [Auteur]
Donat, Ester [Auteur]
Benninga, Marc A. [Auteur]
Broekaert, Ilse J. [Auteur]
Gottrand, fréderic [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Kolho, Kaija-Leena [Auteur]
Lionetti, Paolo [Auteur]
Miele, Erasmo [Auteur]
Orel, Rok [Auteur]
Papadopoulou, Alexandra [Auteur]
Pienar, Corina [Auteur]
Schappi, Michela G. [Auteur]
Wilschanski, Michael [Auteur]
Thapar, Nikhil [Auteur]
Donat, Ester [Auteur]
Benninga, Marc A. [Auteur]
Broekaert, Ilse J. [Auteur]
Gottrand, fréderic [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Kolho, Kaija-Leena [Auteur]
Lionetti, Paolo [Auteur]
Miele, Erasmo [Auteur]
Orel, Rok [Auteur]
Papadopoulou, Alexandra [Auteur]
Pienar, Corina [Auteur]
Schappi, Michela G. [Auteur]
Wilschanski, Michael [Auteur]
Thapar, Nikhil [Auteur]
Titre de la revue :
Journal of Pediatric Gastroenterology and Nutrition
Nom court de la revue :
J Pediatr Gastroenterol Nutr
Numéro :
72
Pagination :
617-640
Date de publication :
2021-04-01
ISSN :
1536-4801
Mot(s)-clé(s) :
position paper
intestine
inflammatory bowel disease
Crohn disease
fecal calprotectin
inflammation
ulcerative colitis
intestine
inflammatory bowel disease
Crohn disease
fecal calprotectin
inflammation
ulcerative colitis
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
OBJECTIVE: The aim of the study was to review the evidence regarding the clinical use and value of fecal calprotectin (FC) measurements in different gastrointestinal disorders in children.
METHODS: A literature search was ...
Lire la suite >OBJECTIVE: The aim of the study was to review the evidence regarding the clinical use and value of fecal calprotectin (FC) measurements in different gastrointestinal disorders in children. METHODS: A literature search was conducted in the PubMed, MEDLINE, EMBASE, and Cochrane databases until October 31, 2019. Subtopics were identified and each assigned to individual authors. RESULTS: A total of 28 recommendations were voted on using the nominal voting technique. Recommendations are given related to sampling, measurement methods, and results interpretation. The 14 authors anonymously voted on each recommendation using a 9-point scale (1 strongly disagree to 9 fully agree). Consensus was considered achieved if at least 75% of the authors voted 6, 7, 8, or 9. CONCLUSIONS: Consensus was reached for all recommendations. Limitations for the use of FC in clinical practice include variability in extraction methodology, performance of test kits as well as the need to establish local reference ranges because of the influence of individual factors, such as age, diet, microbiota, and drugs. The main utility of FC measurement at present is in the diagnosis and monitoring of inflammatory bowel disease (IBD) as well as to differentiate it from functional gastrointestinal disorders (FAPDs). FC, however, has neither utility in the diagnosis of infantile colic nor to differentiate between functional and organic constipation. A rise in FC concentration, may alert to the risk of developing necrotizing enterocolitis and help identifying gastrointestinal involvement in children with Henoch-Schönlein purpura. FC measurement is of little value in Cow's Milk Protein Allergy, coeliac disease (CD), and cystic fibrosis. FC does neither help to distinguish bacterial from viral acute gastroenteritis (AGE), nor to diagnose Helicobacter Pylori infection, small intestinal bacterial overgrowth (SIBO), acute appendicitis (AA), or intestinal polyps.Lire moins >
Lire la suite >OBJECTIVE: The aim of the study was to review the evidence regarding the clinical use and value of fecal calprotectin (FC) measurements in different gastrointestinal disorders in children. METHODS: A literature search was conducted in the PubMed, MEDLINE, EMBASE, and Cochrane databases until October 31, 2019. Subtopics were identified and each assigned to individual authors. RESULTS: A total of 28 recommendations were voted on using the nominal voting technique. Recommendations are given related to sampling, measurement methods, and results interpretation. The 14 authors anonymously voted on each recommendation using a 9-point scale (1 strongly disagree to 9 fully agree). Consensus was considered achieved if at least 75% of the authors voted 6, 7, 8, or 9. CONCLUSIONS: Consensus was reached for all recommendations. Limitations for the use of FC in clinical practice include variability in extraction methodology, performance of test kits as well as the need to establish local reference ranges because of the influence of individual factors, such as age, diet, microbiota, and drugs. The main utility of FC measurement at present is in the diagnosis and monitoring of inflammatory bowel disease (IBD) as well as to differentiate it from functional gastrointestinal disorders (FAPDs). FC, however, has neither utility in the diagnosis of infantile colic nor to differentiate between functional and organic constipation. A rise in FC concentration, may alert to the risk of developing necrotizing enterocolitis and help identifying gastrointestinal involvement in children with Henoch-Schönlein purpura. FC measurement is of little value in Cow's Milk Protein Allergy, coeliac disease (CD), and cystic fibrosis. FC does neither help to distinguish bacterial from viral acute gastroenteritis (AGE), nor to diagnose Helicobacter Pylori infection, small intestinal bacterial overgrowth (SIBO), acute appendicitis (AA), or intestinal polyps.Lire moins >
Langue :
Anglais
Comité de lecture :
Oui
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Date de dépôt :
2021-07-06T12:50:06Z
2024-03-05T10:49:00Z
2024-03-05T10:49:00Z